| Mar 14 |
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
|
| Mar 5 |
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
|
| Mar 4 |
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
|
| Mar 1 |
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
| Feb 20 |
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
|
| Feb 6 |
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
|
| Jan 18 |
David Perry Bought 8.6% More Shares In Better Therapeutics
|
| Jan 17 |
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
|
| Jan 2 |
Better Therapeutics applies for FDA breakthrough designation for NASH device
|
| Jan 2 |
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
|
